Thermo Fisher Scientific TRAIL-R2 (DR5) (soluble) Polyclonal Antibody, PeproTech

Applications and Tested Dilutions

Product Specifications

Product Specific Information

Amino Acid Sequence of Recombinant Protein:
MESALITQQD LAPQQRVAPQ QKRSSPSEGL CPPGHHISED GRDCISCKYG QDYSTHWNDL LFCLRCTRCD SGEVELSPCT TTRNTVCQCE EGTFREEDSP EMCRKCRTGC PRGMVKVGDC TPWSDIECVH KES

Preparation:
Produced from sera of rabbits immunized with highly pure Recombinant Human sTRAIL Receptor-2. Anti-Human sTRAIL Receptor-2-specific antibody was purified by affinity chromatography employing an immobilized Human sTRAIL Receptor-2 matrix.

Sandwich ELISA:
To detect Human sTRAIL Receptor-2 by sandwich ELISA (using 100 µL/well antibody solution), a concentration of 0.5–2.0 µg/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with PeproTech Biotinylated Anti-Human sTRAIL Receptor-2 (500-P299Bt) as a detection antibody, allows the detection of at least 0.2–0.4 ng/well of Recombinant Human sTRAIL Receptor-2.

Western Blot:
To detect hsTRAIL Receptor-2 by Western blot analysis, this antibody can be used at a concentration of 0.1–0.2 µg/mL. Used in conjunction with compatible secondary reagents, the detection limit for Recombinant hsTRAIL Receptor-2 is 1.5–3.0 ng/lane, under either reducing or non-reducing conditions.

Target Information

DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a death domain-containing receptor for TRAIL, mediating TRAIL-induced apoptosis. It belongs to the TNF receptor superfamily and transduces apoptosis signals via FADD. Two transcript variants encoding different isoforms and one non-coding transcript are known. DR5 overexpression induces apoptosis and activates NF-κB. It is highly expressed in lymphocytes and spleen. DR5 dysfunction is associated with squamous cell carcinoma and diffuse infiltrative lymphocytosis syndrome.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.